Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 11/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132733 | 0.77 | CHRNB2 (0.47) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL14317861 | 0.74 | CYP19A1 (0.39) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL14243762 | 0.74 | CYP19A1 (0.39) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL14278881 | 0.70 | CHRNB2 (0.46) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL6435720 | 0.68 | CYP19A1 (0.42) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL12163033 | 0.66 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL9537354 | 0.66 | NTRK1 (0.33) | CYP19A1 | |
| SCHEMBL13983944 | 0.66 | NTRK1 (0.33) | CYP19A1 | |
| SCHEMBL2669662 | 0.66 | CYP11B1 (0.39) | CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL29649344 | 0.66 | CYP11B1 (0.38) | CYP11B2CYP19A1CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076784-A1 | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors | NOVARTIS AG (CH) | 2008-03-27 | — | — | US | disclosed |
| US-20080076784-A1 | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors | NOVARTIS AG (CH) | 2008-03-27 | — | — | US | disclosed |
| US-20080076784-A1 | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors | NOVARTIS AG (CH) | 2008-03-27 | — | — | US | disclosed |
| CN-1968930-A | Bicyclic nitrogen-containing heterocycles as aromatase inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2007-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076784-A1 | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors | CYP19A1, NR5A1, HSD17B11 | CYP11B2 6/4885CYP19A1 1/4885CYP11B1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.